Equity Overview
Price & Market Data
Price: $16.70
Daily Change: -$0.53 / 3.17%
Range: $16.45 - $17.53
Market Cap: $910,034,816
Volume: 11,542
Performance Metrics
1 Week: -0.48%
1 Month: 3.92%
3 Months: 0.18%
6 Months: -8.74%
1 Year: 5.16%
YTD: -12.88%
Company Details
Employees: 108
Sector: Health technology
Industry: Pharmaceuticals: major
Country: Netherlands
Details
Pharvaris N.V., a late-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases with unmet needs covering angioedema and other bradykinin-mediated diseases. The company develops deucrictibant, a small molecule bradykinin B2-receptor antagonist for the treatment of attacks due to bradykinin-mediated angioedema, including hereditary angioedema (HAE) and acquired angioedema due to C1-inhibitor deficiency (AAE-C1INH), as well as in Phase 3 trials for treatment and prophylaxis of HAE attacks; and extended-release tablet and immediate-release capsule formulation of deucrictibant. Pharvaris N.V. was incorporated in 2015 and is headquartered in Zug, Switzerland.